FOA Title: 
Transformative Technology Development for the Human BioMolecular Atlas Program (UG3/UH3 Clinical Trial Not Allowed)
Grant Type: 
RFA-RM-20-001
Primary IC: 
RMOD
Release Date: 
Dec 02 2019
Expiration Date: 
Mar 04 2020
AC Source: 
UG3/UH3
Purpose: 
The purpose of this Funding Opportunity Announcement (FOA) is to solicit transformative technologies that will significantly expand throughput, multiplexing and discrimination of biomolecules in human tissues for comprehensive mapping of individual cells and their context in human tissues. This FOA supports the accelerated proof-of-principle demonstration and validation of promising tools, techniques and systems that can be integrated, scaled and applied to multiple human tissues. The initial two-year UG3 phase will support accelerated development and demonstration of feasibility of these emerging, high impact technologies. The subsequent two-year UH3 phase will support validation in human tissues, optimization, scale-up, and generation of data. Funded projects will be expected to work closely as part of the Human BioMolecular Atlas Program to catalyze development of a framework for mapping the human body with high resolution.